La radiologia medica, ISSN 0033-8362, 10/2018, Volume 123, Issue 10, pp. 788 - 798
According to the European directive 2013/59/Euratom, starting from February 2018, the information relating to patient exposure will be part of computed...
Radiation dose | Questionnaire | Medicine & Public Health | Diagnostic Radiology | Computed tomography | Ionizing radiation risk | Interventional Radiology | Imaging / Radiology | Ultrasound | Dose bill | Neuroradiology | CLINICAL BENEFIT | ERA | PERSONALIZED MEDICINE | ITALIAN NATIONWIDE SURVEY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | COMMUNICATION | ADULT | Medicine, Experimental | Medical research | CT imaging | Ionizing radiation | Diagnostic imaging
Radiation dose | Questionnaire | Medicine & Public Health | Diagnostic Radiology | Computed tomography | Ionizing radiation risk | Interventional Radiology | Imaging / Radiology | Ultrasound | Dose bill | Neuroradiology | CLINICAL BENEFIT | ERA | PERSONALIZED MEDICINE | ITALIAN NATIONWIDE SURVEY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | COMMUNICATION | ADULT | Medicine, Experimental | Medical research | CT imaging | Ionizing radiation | Diagnostic imaging
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 2848 - 2848
Journal Article
Prevention Science, ISSN 1389-4986, 05/2017, Volume 18, Issue 4, pp. 394 - 405
Evidence-based preventive interventions for adolescent substance use, violence, and mental health issues are increasingly being adapted and disseminated...
Cultural adaptation | Evaluation | Evidence-based program | Effectiveness | Drug abuse prevention | SYSTEM | INTERVENTIONS | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | RANDOMIZED-TRIALS | RELIABILITY | Self Efficacy | Substance-Related Disorders - prevention & control | Humans | Adolescent | Italy | Preventive Health Services - organization & administration | Child | Adaptation, Psychological | Prevention | Youth | Substance abuse | Teenagers | Research | Health aspects | Drug abuse | Interest groups | Health services | Cognition | Effects | Middle schools | Training | Design | Students | Skills | Drunkenness | Prevention programs | Education | Addictive behaviors | Mental health services | Behavior | Adolescents | Clinical psychology | Schools | Drug use | Public health | Adaptation | Skill development | Violence | Health promotion | Health care policy | Management | Health education | Health care services policy | Researchers | Drug prevention | Smoking
Cultural adaptation | Evaluation | Evidence-based program | Effectiveness | Drug abuse prevention | SYSTEM | INTERVENTIONS | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | RANDOMIZED-TRIALS | RELIABILITY | Self Efficacy | Substance-Related Disorders - prevention & control | Humans | Adolescent | Italy | Preventive Health Services - organization & administration | Child | Adaptation, Psychological | Prevention | Youth | Substance abuse | Teenagers | Research | Health aspects | Drug abuse | Interest groups | Health services | Cognition | Effects | Middle schools | Training | Design | Students | Skills | Drunkenness | Prevention programs | Education | Addictive behaviors | Mental health services | Behavior | Adolescents | Clinical psychology | Schools | Drug use | Public health | Adaptation | Skill development | Violence | Health promotion | Health care policy | Management | Health education | Health care services policy | Researchers | Drug prevention | Smoking
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 07/2019, Volume 58, Issue 7, pp. 844 - 845
Journal Article
Cancer Cell, ISSN 1535-6108, 07/2018, Volume 34, Issue 1, pp. 148 - 162.e7
Targeting HER2 is effective in 24% of amplified metastatic colorectal cancer; however, secondary resistance occurs in most of the cases. We studied the...
trastuzumab | targeted therapy | rapid autopsy | colorectal cancer | clonal evolution | HER2 amplification | lapatinib | liquid biopsy | ctDNA | resistance | BREAST-CANCER | HETEROGENEITY | PIK3CA MUTATIONS | THERAPY | AMPLIFICATION | SOLID TUMORS | GENE | ONCOLOGY | ACQUIRED-RESISTANCE | EGFR BLOCKADE | PATHOLOGICAL COMPLETE RESPONSE | CELL BIOLOGY | Predictive Value of Tests | ras Proteins - genetics | Liquid Biopsy | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Protein Kinase Inhibitors - adverse effects | Time Factors | DNA Mutational Analysis | Clinical Decision-Making | Colorectal Neoplasms - drug therapy | Female | Adenocarcinoma - genetics | Receptor, ErbB-2 - antagonists & inhibitors | Tumor Cells, Cultured | Liver Neoplasms - secondary | Lapatinib - adverse effects | Liver Neoplasms - genetics | Risk Factors | Liver Neoplasms - drug therapy | Trastuzumab - adverse effects | Mice, Transgenic | Treatment Outcome | Colorectal Neoplasms - diagnostic imaging | Trastuzumab - administration & dosage | Mice, SCID | Adenocarcinoma - drug therapy | Liver Neoplasms - diagnostic imaging | Adenocarcinoma - secondary | Disease Progression | Magnetic Resonance Imaging | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Italy | Mice, Inbred NOD | Adenocarcinoma - diagnostic imaging | Colorectal Neoplasms - pathology | Lapatinib - administration & dosage | Genetic research | Genetic aspects | Metastasis | Analysis | Colorectal cancer | Cancer
trastuzumab | targeted therapy | rapid autopsy | colorectal cancer | clonal evolution | HER2 amplification | lapatinib | liquid biopsy | ctDNA | resistance | BREAST-CANCER | HETEROGENEITY | PIK3CA MUTATIONS | THERAPY | AMPLIFICATION | SOLID TUMORS | GENE | ONCOLOGY | ACQUIRED-RESISTANCE | EGFR BLOCKADE | PATHOLOGICAL COMPLETE RESPONSE | CELL BIOLOGY | Predictive Value of Tests | ras Proteins - genetics | Liquid Biopsy | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Protein Kinase Inhibitors - adverse effects | Time Factors | DNA Mutational Analysis | Clinical Decision-Making | Colorectal Neoplasms - drug therapy | Female | Adenocarcinoma - genetics | Receptor, ErbB-2 - antagonists & inhibitors | Tumor Cells, Cultured | Liver Neoplasms - secondary | Lapatinib - adverse effects | Liver Neoplasms - genetics | Risk Factors | Liver Neoplasms - drug therapy | Trastuzumab - adverse effects | Mice, Transgenic | Treatment Outcome | Colorectal Neoplasms - diagnostic imaging | Trastuzumab - administration & dosage | Mice, SCID | Adenocarcinoma - drug therapy | Liver Neoplasms - diagnostic imaging | Adenocarcinoma - secondary | Disease Progression | Magnetic Resonance Imaging | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Italy | Mice, Inbred NOD | Adenocarcinoma - diagnostic imaging | Colorectal Neoplasms - pathology | Lapatinib - administration & dosage | Genetic research | Genetic aspects | Metastasis | Analysis | Colorectal cancer | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 581 - 581
581 Background: We have reported with the HERACLES Trial that HER2 amplification is a clinically relevant genetic alteration in metastatic colorectal cancer...
Journal Article
2018, 1, ISBN 9781138193574, Volume 1
This chapter shows that two different components: a historical overview of disability in Italy from Roman times up to the 19th century, and the evolution of...
Book Chapter
BMC Medicine, ISSN 1741-7015, 07/2016, Volume 14, Issue 1, p. 106
Background: To date, delirium prevalence in adult acute hospital populations has been estimated generally from pooled findings of single-center studies and/or...
Delirium | Prevalence | Hospital | Multicenter | 4AT | MORTALITY | DEMENTIA | ASSOCIATIONS | QUALITATIVE EVALUATION | SYMPTOMS | HIP FRACTURE PATIENTS | CARE | MEDICINE, GENERAL & INTERNAL | ELDERLY MEDICAL INPATIENTS | POSTOPERATIVE DELIRIUM | PEOPLE | Delirium - epidemiology | Prospective Studies | Cross-Sectional Studies | Humans | Logistic Models | Male | Inpatients - statistics & numerical data | Aged, 80 and over | Female | Italy - epidemiology | Surveys and Questionnaires | Aged | Odds Ratio | Delirium - diagnosis | Psychological aspects | Aged patients | Statistics | Health aspects
Delirium | Prevalence | Hospital | Multicenter | 4AT | MORTALITY | DEMENTIA | ASSOCIATIONS | QUALITATIVE EVALUATION | SYMPTOMS | HIP FRACTURE PATIENTS | CARE | MEDICINE, GENERAL & INTERNAL | ELDERLY MEDICAL INPATIENTS | POSTOPERATIVE DELIRIUM | PEOPLE | Delirium - epidemiology | Prospective Studies | Cross-Sectional Studies | Humans | Logistic Models | Male | Inpatients - statistics & numerical data | Aged, 80 and over | Female | Italy - epidemiology | Surveys and Questionnaires | Aged | Odds Ratio | Delirium - diagnosis | Psychological aspects | Aged patients | Statistics | Health aspects
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2016, Volume 11, Issue 6, p. e0156658
PAX8 is a thyroid-specific transcription factor whose expression is dysregulated in thyroid cancer. A recent study using a conditional knock-out mouse model...
BREAST-CANCER | NGAL | CELLS | PROTEIN | GLYPICAN-3 EXPRESSION | MULTIDISCIPLINARY SCIENCES | GELATINASE-ASSOCIATED LIPOCALIN | DIFFERENTIATION | COMBINATION | TUMORS | HEDGEHOG | PAX8 Transcription Factor - genetics | Thyroid Neoplasms - genetics | Carcinoma, Papillary - genetics | Animals | Humans | RNA, Messenger - genetics | Mice | Principal Component Analysis | Mice, Knockout | Thyroid cancer | Physiological aspects | Development and progression | Genetic aspects | Research | Gene expression | Cancer | Medicine | Heparan sulfate | Studies | Transcription factors | Hospitals | Internal medicine | Neutrophils | Oncology | Tumors
BREAST-CANCER | NGAL | CELLS | PROTEIN | GLYPICAN-3 EXPRESSION | MULTIDISCIPLINARY SCIENCES | GELATINASE-ASSOCIATED LIPOCALIN | DIFFERENTIATION | COMBINATION | TUMORS | HEDGEHOG | PAX8 Transcription Factor - genetics | Thyroid Neoplasms - genetics | Carcinoma, Papillary - genetics | Animals | Humans | RNA, Messenger - genetics | Mice | Principal Component Analysis | Mice, Knockout | Thyroid cancer | Physiological aspects | Development and progression | Genetic aspects | Research | Gene expression | Cancer | Medicine | Heparan sulfate | Studies | Transcription factors | Hospitals | Internal medicine | Neutrophils | Oncology | Tumors
Journal Article
Muscle & Nerve, ISSN 0148-639X, 11/2013, Volume 48, Issue 5, pp. 837 - 838
NEUROSCIENCES | CLINICAL NEUROLOGY | Humans | Middle Aged | Osteomalacia - complications | Anticonvulsants - administration & dosage | Male | Treatment Outcome | Bone Density Conservation Agents - administration & dosage | Muscular Diseases - etiology | Muscular Diseases - diagnosis | Osteomalacia - chemically induced | Osteomalacia - diagnosis | Anticonvulsants - adverse effects | Carbamazepine - adverse effects | Cholecalciferol - administration & dosage | Carbamazepine - administration & dosage | Phenobarbital - administration & dosage | Osteomalacia - drug therapy | Muscular Diseases - drug therapy | Epilepsy - drug therapy | Muscular Diseases - chemically induced | Phenobarbital - adverse effects | Complications and side effects | Anticonvulsants
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 02/2017, Volume 119, Issue 3, pp. 483 - 489
Hypertensive hypokinetic cardiomyopathy (HHC) is defined by left ventricular (LV) systolic dysfunction with a history of systemic hypertension as the only...
CARDIAC & CARDIOVASCULAR SYSTEMS | TASK-FORCE | MYOCARDIAL FIBROSIS | HEART-FAILURE | GUIDELINES | CLASSIFICATION | ECHOCARDIOGRAPHY | EUROPEAN-SOCIETY | ASSOCIATION | LEFT-VENTRICULAR HYPERTROPHY | PROGRESSION | Humans | Middle Aged | Heart Failure - physiopathology | Male | Cardiomyopathies - etiology | Cause of Death | Heart Failure - therapy | Ventricular Dysfunction, Left - therapy | Cardiomyopathies - physiopathology | Ventricular Remodeling | Amiodarone - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Tachycardia, Ventricular - epidemiology | Adult | Female | Retrospective Studies | Ventricular Fibrillation - epidemiology | Heart Failure - etiology | Heart-Assist Devices | Adrenergic beta-Antagonists - therapeutic use | Hypertrophy, Left Ventricular - etiology | Mortality | Ventricular Dysfunction, Left - etiology | Heart Transplantation | Anti-Arrhythmia Agents - therapeutic use | Disease Progression | Ventricular Dysfunction, Left - physiopathology | Cardiomyopathies - therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Stroke Volume | Hypertrophy, Left Ventricular - therapy | Cardiomyopathy, Dilated - physiopathology | Hypertension - complications | Aged | Hypertrophy, Left Ventricular - physiopathology | Angiotensin Receptor Antagonists - therapeutic use | Cardiomyopathy, Dilated - therapy | Hypertension | Comorbidity | Analysis | Cardiomyopathy, Dilated | Electrocardiography | Cardiac arrhythmia | Cardiovascular disease
CARDIAC & CARDIOVASCULAR SYSTEMS | TASK-FORCE | MYOCARDIAL FIBROSIS | HEART-FAILURE | GUIDELINES | CLASSIFICATION | ECHOCARDIOGRAPHY | EUROPEAN-SOCIETY | ASSOCIATION | LEFT-VENTRICULAR HYPERTROPHY | PROGRESSION | Humans | Middle Aged | Heart Failure - physiopathology | Male | Cardiomyopathies - etiology | Cause of Death | Heart Failure - therapy | Ventricular Dysfunction, Left - therapy | Cardiomyopathies - physiopathology | Ventricular Remodeling | Amiodarone - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Tachycardia, Ventricular - epidemiology | Adult | Female | Retrospective Studies | Ventricular Fibrillation - epidemiology | Heart Failure - etiology | Heart-Assist Devices | Adrenergic beta-Antagonists - therapeutic use | Hypertrophy, Left Ventricular - etiology | Mortality | Ventricular Dysfunction, Left - etiology | Heart Transplantation | Anti-Arrhythmia Agents - therapeutic use | Disease Progression | Ventricular Dysfunction, Left - physiopathology | Cardiomyopathies - therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Stroke Volume | Hypertrophy, Left Ventricular - therapy | Cardiomyopathy, Dilated - physiopathology | Hypertension - complications | Aged | Hypertrophy, Left Ventricular - physiopathology | Angiotensin Receptor Antagonists - therapeutic use | Cardiomyopathy, Dilated - therapy | Hypertension | Comorbidity | Analysis | Cardiomyopathy, Dilated | Electrocardiography | Cardiac arrhythmia | Cardiovascular disease
Journal Article
International journal of dermatology, 07/2019, Volume 58, Issue 7, p. 844
Journal Article
Endocrine-Related Cancer, ISSN 1351-0088, 04/2016, Volume 23, Issue 4, pp. 335 - 347
Anaplastic thyroid carcinoma (ATC) is an extremely aggressive thyroid cancer subtype, refractory to the current medical treatment. Among various epigenetic...
BET | Epigenetics | MCM5 | RNA-seq | METASTASES | MECHANISMS | epigenetics | LINES | REPLICATION | ONCOLOGY | MYC | ENDOCRINOLOGY & METABOLISM | BROMODOMAIN INHIBITION | PROTEINS | EXPRESSION | HISTONE DEACETYLASE | CYCLE | Cell Survival - drug effects | Benzodiazepines - pharmacology | Apoptosis - drug effects | Humans | Cell Cycle Proteins - metabolism | Neoplasm Proteins - antagonists & inhibitors | Mice, Knockout | Azepines - pharmacology | Triazoles - pharmacology | Animals | Nuclear Proteins - antagonists & inhibitors | Cell Cycle Proteins - genetics | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Carcinoma - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - genetics | Nuclear Proteins - genetics | Thyroid Gland - metabolism | Thyroid Neoplasms - metabolism
BET | Epigenetics | MCM5 | RNA-seq | METASTASES | MECHANISMS | epigenetics | LINES | REPLICATION | ONCOLOGY | MYC | ENDOCRINOLOGY & METABOLISM | BROMODOMAIN INHIBITION | PROTEINS | EXPRESSION | HISTONE DEACETYLASE | CYCLE | Cell Survival - drug effects | Benzodiazepines - pharmacology | Apoptosis - drug effects | Humans | Cell Cycle Proteins - metabolism | Neoplasm Proteins - antagonists & inhibitors | Mice, Knockout | Azepines - pharmacology | Triazoles - pharmacology | Animals | Nuclear Proteins - antagonists & inhibitors | Cell Cycle Proteins - genetics | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Carcinoma - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - genetics | Nuclear Proteins - genetics | Thyroid Gland - metabolism | Thyroid Neoplasms - metabolism
Journal Article
Cancers, ISSN 2072-6694, 11/2019, Volume 11, Issue 11, p. 1753
Triple negative breast cancer (TNBC) patients not attaining pathological Complete Response (pCR) after neo-adjuvant chemotherapy (NAC) have poor prognosis. We...
somatic mutations | cancer therapy | biopsies | targeted-gene sequencing | neo-adjuvant chemotherapy | triple negative breast cancer | heterogeneity
somatic mutations | cancer therapy | biopsies | targeted-gene sequencing | neo-adjuvant chemotherapy | triple negative breast cancer | heterogeneity
Journal Article
Muscle & Nerve, ISSN 0148-639X, 11/2013, Volume 48, Issue 5, pp. 837 - 838
Journal Article
Schede Medievali, ISSN 0392-5404, 01/1987, Volume 12, p. 1
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 12/2017, Volume 141, pp. 404 - 416
Neuroinflammation is the earliest stage of several neurological and neurodegenerative diseases. In the case of neurodegenerative disorders, it takes place...
Mofezolac | Cyclooxygenase-1 inhibition | Caco-2 cell line | Galmof | GLUT-1 | Molecular modeling | Caco-2 cell line | CHEMISTRY, MEDICINAL | ANALOGS | DIARYLISOXAZOLES | COX-1 INHIBITORS | VALIDATION | MOLECULAR INTERACTION FIELDS | TRANSPORT | DATA SET | PHARMACOPHORE ELUCIDATION | INFLAMMATION | CACO-2 CELLS | Cell Line | Central Nervous System - metabolism | Galactose - pharmacology | Humans | Models, Molecular | Glucose Transporter Type 1 - metabolism | Cyclooxygenase Inhibitors - chemistry | Structure-Activity Relationship | Isoxazoles - chemistry | Blood-Brain Barrier - drug effects | Cyclooxygenase Inhibitors - pharmacology | Dose-Response Relationship, Drug | Isoxazoles - pharmacology | Galactose - chemistry | Animals | Cyclooxygenase Inhibitors - chemical synthesis | Central Nervous System - drug effects | Mice | Molecular Structure | Cyclooxygenase 1 - metabolism | Glucose Transporter Type 1 - antagonists & inhibitors | Proteins | COX-2 inhibitors | Nervous system diseases | Galactose | Analysis
Mofezolac | Cyclooxygenase-1 inhibition | Caco-2 cell line | Galmof | GLUT-1 | Molecular modeling | Caco-2 cell line | CHEMISTRY, MEDICINAL | ANALOGS | DIARYLISOXAZOLES | COX-1 INHIBITORS | VALIDATION | MOLECULAR INTERACTION FIELDS | TRANSPORT | DATA SET | PHARMACOPHORE ELUCIDATION | INFLAMMATION | CACO-2 CELLS | Cell Line | Central Nervous System - metabolism | Galactose - pharmacology | Humans | Models, Molecular | Glucose Transporter Type 1 - metabolism | Cyclooxygenase Inhibitors - chemistry | Structure-Activity Relationship | Isoxazoles - chemistry | Blood-Brain Barrier - drug effects | Cyclooxygenase Inhibitors - pharmacology | Dose-Response Relationship, Drug | Isoxazoles - pharmacology | Galactose - chemistry | Animals | Cyclooxygenase Inhibitors - chemical synthesis | Central Nervous System - drug effects | Mice | Molecular Structure | Cyclooxygenase 1 - metabolism | Glucose Transporter Type 1 - antagonists & inhibitors | Proteins | COX-2 inhibitors | Nervous system diseases | Galactose | Analysis
Journal Article
Haemophilia, ISSN 1351-8216, 07/2019, Volume 25, Issue 4, pp. 656 - 667
Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with...
haemophilia | factor VIII inhibitor | immunization | bleeding disorder | vaccination | BLEEDING DISORDERS | FACTOR-VIII | GUIDELINES | CHILDREN | HEPATITIS-B VACCINATION | INHIBITOR DEVELOPMENT | UPDATE | HEMATOLOGY | VACCINES | Care and treatment | Blood coagulation factor VIII | Communicable diseases | Vaccination | Hemophilia
haemophilia | factor VIII inhibitor | immunization | bleeding disorder | vaccination | BLEEDING DISORDERS | FACTOR-VIII | GUIDELINES | CHILDREN | HEPATITIS-B VACCINATION | INHIBITOR DEVELOPMENT | UPDATE | HEMATOLOGY | VACCINES | Care and treatment | Blood coagulation factor VIII | Communicable diseases | Vaccination | Hemophilia
Journal Article